PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fluticasone furoate→

Fluticasone Furoate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
397864-44-7
PubChem CID
9854489
Molecular formula
C27H29F3O6S
Molecular weight
538.6 g/mol
Drug class
Synthetic glucocorticoidintranasal/inhaled corticosteroid anti-inflammatory agent
Mechanism of action
Activates intracellular glucocorticoid receptors and suppresses inflammatory cytokines and mediator release in airway and nasal tissues. The clinical mechanism depends on the route and whether fluticasone furoate is used alone or in a fixed combination.
Indications / reported uses
  • Treatment of allergic rhinitis symptoms with intranasal fluticasone furoate products
  • Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) only in authorised fixed combinations with a long-acting bronchodilator; fluticasone monotherapy and combination-product indications are not interchangeable

Sources: US DailyMed — Fluticasone furoate nasal spray · US DailyMed — BREO ELLIPTA (fluticasone furoate/vilanterol) · FDA product information

Identification source: PubChem record (CID 9854489). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fluticasone Furoate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fluticasone Furoate Permitted Daily Exposure (PDE) report (the Fluticasone Furoate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fluticasone Furoate Occupational Exposure Limit (OEL) report (the Fluticasone Furoate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.